[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
The patient was a 62-year-old man with small-cell lung cancer (limited disease). He was treated with cisplatin (CDDP) plus etoposide(ETP) and concurrent radiotherapy as first-line treatment. Although a complete response was achieved, his pro-GRP elevated 10 months later. He was treated with several anticancer agents including, CDDP plus irinotecan (CPT-11), CPT-11, paclitaxel and amrubicin (AMR). Although, as a monotherapy, the administration of AMR (30 mg/m(2)) for 3 consecutive days (3-day schedule) seemed to be most effective, severe myelosuppression was observed, and this treatment was discontinued. We changed the treatment schedule to biweekly administration of AMR (30 mg/m(2)). The level of pro-GRP decreased, and it was maintained at a similar level for 7 months. No severe toxicity was observed during this period. This case suggests that the bi-weekly administration of AMR may be a useful option for the treatment of small-cell lung cancer when a 3-day AMR schedule is highly myelosuppressive.
Kurai
Jun
J
Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University.
Igishi
Tadashi
T
Suyama
Hisashi
H
Kodani
Masahiro
M
Fukuoka
Yasushi
Y
Miyata
Masanori
M
Touge
Hirokazu
H
Hasegawa
Yasuaki
Y
Yasuda
Kazuto
K
Hitsuda
Yutaka
Y
Shimizu
Eiji
E
D018943:Anthracyclines / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D018943:Anthracyclines; D005047:Etoposide; D000077146:Irinotecan; C055866:amrubicin; D002945:Cisplatin; D002166:Camptothecin